Chief Medical Officer · 4D Molecular Therapeutics, Inc. (FDMT)

Robert Kim

FY2023 is the first fiscal year CompBrief holds for Robert Kim as a named executive officer of 4D Molecular Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$3,964,950

Salary $456,075Stock awards $0

3rd of 3 named executive officers at 4D Molecular Therapeutics by FY2023 total.

3 named officers on file for 4D Molecular Therapeutics, FY2023

Robert Kim’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how 4D Molecular Therapeutics’s whole pay program stands against its peers

  • 4D Molecular Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FDMT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 10, 2024 (DEF 14A).

Free

Get Robert Kim’s full pay file as a PDF — free

More than this page: up to 10 years of Robert’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Robert Kim compensation by year

4D Molecular Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as 4D Molecular Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$456,075
Bonus$0
Stock awards$0
Option awards$3,260,107
Non-equity incentive$232,268
Pension and deferred compensation$0
All other$16,500
Total$3,964,950

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 10, 2024, accession 0001140361-24-019090, and prior-year filings. Open the filing on EDGAR.

How this page was built: the 4D Molecular Therapeutics, Inc. filed document, accession 0001140361-24-019090. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option250,000—$14.42
Option31,250—$18.66
Option37,917—$15.78
Option41,250—$8.04
Option31,667—$20.24
Option8,125—$15.71

Per the Outstanding Equity Awards at Fiscal Year-End table in 4D Molecular Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

4D Molecular Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
David KirnChief Executive Officer$10,286,808
Fariborz KamalChief Operating Officer & President$4,544,260
Robert Kim · this pageChief Medical Officer$3,964,950

The full 4D Molecular Therapeutics compensation record

free company brief

This page is one person within 4D Molecular Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 4D Molecular Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Robert Kim's compensation dossier · One-time report. No refunds.